Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant

Abstract Objectives The emergence of a SARS‐CoV‐2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020. With an increased infection and transmission rate, it is imperative to determine whether antibodies induced against the D...

Full description

Bibliographic Details
Main Authors: Cheryl Yi‐Pin Lee, Siti Naqiah Amrun, Rhonda Sin‐Ling Chee, Yun Shan Goh, Tze‐Minn Mak, Sophie Octavia, Nicholas Kim‐Wah Yeo, Zi Wei Chang, Matthew Zirui Tay, Anthony Torres‐Ruesta, Guillaume Carissimo, Chek Meng Poh, Siew‐Wai Fong, Wang Bei, Sandy Lee, Barnaby Edward Young, Seow‐Yen Tan, Yee‐Sin Leo, David C Lye, Raymond TP Lin, Sebastien Maurer‐Stroh, Bernett Lee, Cheng‐I Wang, Laurent Renia, Lisa FP Ng
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Clinical & Translational Immunology
Subjects:
clade
COVID‐19
cross‐reactivity
D614G variant
neutralising antibodies
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/cti2.1241

Internet

https://doi.org/10.1002/cti2.1241

Similar Items